Emerging treatment strategies in tourette syndrome: What's in the pipeline?

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 445-480

  Termine, Cristiano ^a   Selvini, Claudia ^a   Rossi, Giorgio ^a   Balottin, Umberto ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Atypical neuroleptics; Electroconvulsive therapy; Newest atypical antipsychotic agents; Pharmacotherapy; Repetitive transcranial magnetic stimulation; Tourette syndrome

Indexed keywords

ARIPIPRAZOLE; BACLOFEN; BOTULINUM TOXIN A; BUSPIRONE; CARBAMAZEPINE; CLONIDINE; ETIRACETAM; FINASTERIDE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; METOCLOPRAMIDE; NALOXONE; NICOTINE; NORADRENALIN; PALIPERIDONE; PHYSOSTIGMINE; PIMOZIDE; PLACEBO; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; SERTINDOLE; SPIRADOLINE MESILATE; SULPIRIDE; TETRABENAZINE; TETRAHYDROCANNABINOL; TIAPRIDE; TOPIRAMATE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; CANADA; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EUROPE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; HYPERSEXUALITY; INSULIN BLOOD LEVEL; LANGUAGE DISABILITY; LIPID BLOOD LEVEL; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL EXPERT; METABOLIC SYNDROME X; MOOD CHANGE; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TIC; TRANSCRANIAL MAGNETIC STIMULATION; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ATYPICAL NEUROLEPTICS; ELECTROCONVULSIVE THERAPY; NEWEST ATYPICAL ANTIPSYCHOTIC AGENTS; PHARMACOTHERAPY; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; TOURETTE SYNDROME;

ELECTROCONVULSIVE THERAPY; EMERGENCY MEDICAL SERVICES; HUMANS; NEUROTRANSMITTER AGENTS; TOURETTE SYNDROME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84888414739     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00015-9     Document Type: Chapter

References (114)

1. Abuzzahab F.S., Brown V.L. Control of Tourette's syndrome with topiramate. The American Journal of Psychiatry 2001, 158:968.
2. Albin R.L., Mink J.W. Recent advances in Tourette syndrome research. Trends in Neurosciences 2006, 29:1715-1782.
3. Allen A.J., Kurlan R.M., Gilbert D.L., Coffey B.J., Linder S.L., Lewis D.W., et al. Atomoxetine treatment in children and adolescents with ADHD and comorbidtic disorders. Neurology 2005, 2005:1941-1949.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorder. DSM-IV-TR 2000, Author, Washington, DC. 4th ed.
5. Anca M.H., Giladi N., Korczyn A.D. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004, 62:1626-1627.
6. Astrup A., Greenway F.L., Ling W., Pedicone L., Lachowicz J., Strader C.D., et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity 2007, 15:1717-1731.
7. Awaad Y. Tics in Tourette syndrome: New treatment options. Journal of Child Neurology 1999, 14:316-319.
8. Awaad Y. Accidental overdosage of levetiracetam in two children caused no side effects. Epilepsy & Behavior 2007, 11:247.
9. Awaad Y., Michon A.M., Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Movement Disorders 2005, 20:714-718.
10. Bloch M.H. Emerging treatments for Tourette's disorder. Current Psychiatry Reports 2008, 10:323-330.
11. Bloch M.H., Peterson B.S., Scahill L., Otka J., Katsovich L., Zhang H., et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Archives of Pediatrics & Adolescent Medicine 2006, 160:65-69.
12. Bloch M., State M., Pittenger C. Recent advances in Tourette syndrome. Current Opinion in Neurology 2011, 24:119-125.
13. Bruun R.D., Budman C.L. Risperidone as a treatment for Tourette's syndrome. The Journal of Clinical Psychiatry 1996, 57:29-31.
14. Calarge C.A., Acion L., Kuperman S., Tansey M., Schlechte J.A. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2009, 19:101-109.
15. Cavanna A.E., Servo S., Monaco F., Robertson M.M. The behavioral spectrum of Gilles de la Tourette syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences 2009, 21:13-23.
16. Chae J.H., Nahas Z., Wassermann E., Li X., Sethuraman G., Gilbert D., et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette's syndrome. Cognitive and Behavioral Neurology 2004, 17:109-117.
17. Cheon K.A., Ryu Y.H., Namkoong K., Kim C.H., Kim J.J., Lee J.D. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Research 2004, 130:85-95.
18. Chipkin R.E., Iorio L.C., Coffin V.L., McQuade R.D., Berger J.G., Barnett A. Pharmacologica profile of SCH39166: A dopamine D1 selective benzophtazepine with potential antipsychotic activity. Journal of Pharmacology Experimental Therapeutics 1988, 247:1093-1102.
19. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 2007, 93:117-130.
20. Dehning S., Feddersen B., Mehrkens J.H., Müller N. Long-term results of electroconvulsive therapy in severe Gilles de la Tourette syndrome. The Journal of ECT 2011, 27:145-147.
21. Dhossche D.M., Reti I.M., Shettar S.M., Wachtel L.E. Tics as signs of catatonia: Electroconvulsive therapy response in 2 men. The Journal of ECT 2010, 26:266-269.
22. Diantoniis M.R., Henry K.M., Partridge P.A., Soucar E. Tics and risperidone. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:839-840.
23. Dion, Y., & Chouinard, G. (1987). Treatment of Gilles de la Tourette syndrome with clonazepam. In 10th Annual meeting of Canadian College of Neuropsychopharmacology, CCNP, May 19-22, p.w.-17. Rivotril G.6453.
24. Drtilkova I., Balaotikova B., Lemanova H., Zak J. Therapeutic effects of clonidine and clonazepam in children with tick syndrome. Homeostasis in Health and Disease 1994, 35:296.
25. Eddy C.M., Rizzo R., Gulisano M., Agodi A., Barchitta M., Calì P., et al. Quality of life in young people with Tourette syndrome: A controlled study. Journal of Neurology 2011, 258(2):291-301. 10.1007/s00415-010-5754-6.
26. Farooq M.U., Bhatt A., Majid A., Gupta R., Khasnis A., Kassab M.Y. Levetiracetam for managing neurologic and psychiatric disorders. American Journal of Health-System Pharmacy 2009, 66:541-561.
27. Fernandez-Jaen A., Fernandez-Mayoralas D.M., Munoz-Jareno N., Calleja-Perez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. European Journal of Paediatric Neurology 2009, 13:541-545.
28. Finis J., Enticott P.G., Pollok B., Münchau A., Schnitzler A., Fitzgerald P.B. Repetitive transcranial magnetic stimulation of the supplementary motor area induces echophenomena. Cortex 2012, 49:1978-1982.
29. Gabbay V., Babb J.S., Klein R.G., Panzer A.M., Katz Y., Alonso C.M., et al. A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder. Pediatrics 2012, 129(6):e1493-e1500. 10.1542/peds.2011-3384.
30. Gaffney G.R., Perry P.J., Lund B.C., Bever-Stille K.A., Arndt S., Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:330-336.
31. Gilbert D. Treatment of children and adolescents with tics and Tourette syndrome. Journal of Child Neurology 2006, 21:690-700.
32. Gilbert D.L., Zhang J., Lipps T.D., Natarajan N., Brandyberry J., Wang Z., et al. Atomoxetine treatment of ADHD in Tourette Syndrome: Reduction in motor cortex inhibition correlates with clinical improvement. Clinical Neurophysiology 2007, 118:1835-1841.
33. Goetz C.G. Clonidine and clonazepam in Tourette syndrome. Advances in Neurology 1992, 58:245-251.
34. Gonce M., Barbeau A. Seven cases of Gilles de la Tourette's syndrome: Partial relief with clonazepam: A pilot study. The Canadian Journal of Neurological Sciences 1977, 4:279-283.
35. Grant J.E., Odlaug B.L., Kim S.W. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Archives of General Psychiatry 2009, 66:756-763.
36. Harris K., Singer H.S. Tic disorders: Neural circuits, neurochemistry, and neuroimmunology. Journal of Child Neurology 2006, 21:678-689.
37. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatric Neurology 2009, 40:420-425.
38. Herman B.H., Hammock M.K., Arthur-Smith A., Egan J., Chatoor I., Werner A., et al. Naltrexone decreases self-injurious behavior. Annals of Neurology 1987, 22:550-552.
39. Hou D., Schumacher D. The selection of a commercial route for the D1 antagonist Sch-39166. Current Opinion in Drug Discovery & Development 2001, 4:792-799.
40. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2010, 81:70-73.
41. Jankovic J., Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. The Canadian Journal of Neurological Sciences 1987, 14:541-546.
42. Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research 2007, 90:147-161.
43. Karadenizli D., Dilbaz N., Bayam G. Gilles de la Tourette syndrome: Response to electroconvulsive therapy. The Journal of ECT 2005, 21:246-248.
44. Kastrup A., Schlotter W., Plewnia C., Bartels M. Treatment of tics in Tourette syndrome with aripiprazole. Journal of Clinical Psychopharmacology 2005, 25:94-96.
45. Kaim B. A case of Gilles de la Tourette's syndrome treated with clonazepam. Brain Research Bullettin 1983, 11:213-214.
46. Kuo S.H., Jimenez-Shahed J. Topiramate in treatment of Tourette syndrome. Clinical Neuropharmacology 2010, 33:32-34.
47. Kurlan R., Crespi G., Coffey B., Mueller-Vahl K., Koval S., Wunderlich G., et al. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Movement Disorders 2012, 27:775-778.
48. Kurlan R., Majumdar L., Deeley C., Mudholkar G.S., Plumb S., Como P.G. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Annals of Neurology 1991, 30:19-23.
49. Kwak C., Dat Vuong K., Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Movement Disorders 2003, 18:1530-1533.
50. Kwon H.J., Lim W.S., Lim M.H., Lee S.J., Hyun J.K., Chae J.H., et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette's syndrome. Neuroscience Letters 2011, 492:1-4.
51. Le K., Liu L., Sun M., Hu L., Xiao N. Transcranial magnetic stimulation at 1 Hertz improves clinical symptoms in children with Tourette syndrome for at least 6 months. Journal of Clinical Neuroscience 2013, 20:257-262.
52. Leckman J.F. Tic disorders: New European guidelines highlight best practice in diagnosis and management. BMJ 2012, 343:d7659.
53. Lerner A., Bagic A., Simmons J.M., Mari Z., Bonne O., Xu B., et al. Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain 2012, 135:1926-1936.
54. Lombroso P.J., Scahill L., King R.A., Lynch K.A., Chappell P.B., Peterson B.S., et al. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 1995(34):1147-1152.
55. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9861-9866.
56. Mantovani A., Leckman J.F., Grantz H., King R.A., Sporn A.L., Lisanby S.H. Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: Report of two cases. Clinical Neurophysiology 2007, 118:2314-2315.
57. Mantovani A., Lisanby S.H., Pieraccini F., Ulivelli M., Castrogiovanni P., Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). The International Journal of Neuropsychopharmacology 2006, 9:95-100.
58. Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., et al. Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 2007, 62:1363-1370.
59. Martínez-Granero M.A., García-Pérez A., Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatric Disease and Treatment 2010, 24:309-316.
60. Merikangas J.R., Merikangas K.R., Kopp U., Hanin I. Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta Psychiatrica Scandinavica 1985, 72:395-399.
61. Minzer K., Lee O., Hong J.J., Singer H.S. Increased prefrontal D2 protein in Tourette syndrome: A postmortem analysis of frontal cortex and striatum. Journal of the Neurological Sciences 2004, 219:55-61.
62. Morais S.L., Derenusson G.N., Pinto J.P., Hounie A.G., Dursun S.M., Wichert-Ana L., et al. Neurobiological substrates of electroconvulsive therapy for Tourette syndrome: A serial SISCOM study. The Journal of ECT 2007, 23:278-280.
63. Mothet J.P., Parent A.G., Wolosker H., Brady R.O., Linden D.J., Ferris C.D., et al. d-Serdine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4926-4931.
64. Mrakic-Sposta S., Marceglia S., Mameli F., Dilena R., Tadini L., Priori A. Transcranial direct current stimulation in two patients with Tourette syndrome. Movement Disorder 2008, 23:2259-2261.
65. Müller-Vahl K.R. Surgical treatment of Tourette syndrome. Neuroscience and Biobehavioral Reviews 2013, 37:1178-1185.
66. Muller-Vahl K., Dodel I., Muller N., Munchau A., Reese J.P., Balzer-Geldsetzer M., et al. Health-related quality of life in patients with Gilles de la Tourette's syndrome. Movement Disorders 2010, 25:309-314.
67. Müller-Vahl K.R., Meyer G.J., Knapp W.H., Emrich H.M., Gielow P., Brücke T., et al. Serotonin transporter binding in Tourette Syndrome. Neuroscience Letters 2005, 385:120-125.
68. Munchau A., Bloem B.R., Thilo K.V., Trimble M.R., Rothwell J.C., Robertson M.M. Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology 2002, 59:1789-1791.
69. Noyer M., Gillard M., Matagne A., Hénichart J.P., Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Clinical Pharmacology 1995, 286:137-146.
70. Oulis P., Karapoulios E., Masdrakis V.G., Kouzoupis A.V., Karakatsanis N.A., Papageorgiou C., et al. Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome. The World Journal of Biological Psychiatry 2008, 9:76-77.
71. Paba S., Frau R., Godar S.C., Devoto P., Marrosu F., Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Current Pharmaceutical Design 2011, 17:151-167.
72. Pae C.U., Serretti A., Chiesa A., Mandelli L., Lee C., Lee C., et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. European Neuropsychopharmacology 2009, 19:562-570.
73. Perwien A.R., Kratochvil C.J., Faries D.E., Vaughan B.S., Spencer T., Brown R.T. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-lifeoutcomes?. Journal of Child and Adolescent Psychopharmacology 2006, 16:713-724.
74. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. The British Journal of Psychiatry 1995, 166:712-726.
75. Porta M., Menghetti C., Sassi M., Brambilla A., Defendi S., Servello D., et al. Treatment-refractory Tourette syndrome. Giorn Ital Psicopat 2011, 17:225-233.
76. Poulain P., Margineanu D.G. Levetiracetam opposes the action of GABA-A antagonists in hypothalamic neurones. Neuropharmacology 2002, 42:346-352.
77. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Canadian Journal of Psychiatry 2012, 57:133-143.
78. Rapoport M., Feder V., Sandor P. Response of major depression and Tourette's syndrome to ECT: A case report. Psychosomatic Medicine 1998, 60:528-529.
79. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology 2002, 136:659-672.
80. Rindner E.C. Living with Tourette's syndrome. Journal of Psychosocial Nursing and Mental Health Services 2007, 4:19-23.
81. Rippel C.A., Kobets A.J., Yoon D.Y., Williams P.N., Shugart Y.Y., Bridges D.D., et al. Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder: No evidence for significant association. Psychiatric Genetics 2006, 16:179-180.
82. Rizzo R., Gulisano M., Calì P.V., Curatolo P. Tourette syndrome and comorbid ADHD: Current pharmacological treatment options. European Journal of Paediatric Neurology 2013, 17:421-428.
83. Robertson M.M., Eapen V., Cavanna A.E. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: A cross-cultural perspective. Journal of Psychosomatic Research 2009, 67:475-483.
84. Robertson M.M., Stern J.S. Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. European Child and Adolescent Psychiatry 2000, 9:60-75.
85. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child and Adolescent Psychiatry 2011, 20:173-196.
86. Rojas-Corrales M.O., Gibert-Rahola J., Mico J.A. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology 2007, 190:221-231.
87. Saddichha S., Ameen S., Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 2008, 28:27-31.
88. Scahill L., Erenberg G., Berlin C.M., Budman C., Coffey B.J., Jankovic J., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192-206.
89. Serra-Mestres J., Ring H.A., Costa D.C., Gacinovic S., Walker Z., Lees A.J., et al. Dopamine transporter binding in Gilles de la Tourette syndrome: A [123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica 2004, 109:140-146.
90. Shapiro A.K. Gilles de la Tourette syndrome 1988, Raven, New York.
91. Shulman L.M., Singer C., Weiner W.J. Risperidone in Gilles de la Tourette syndrome. Neurology 1995, 45:1419.
92. Singer H.S. Treatment of tics and Tourette syndrome. Current Treatment Options in Neurology 2010, 12:539-561.
93. Singer H.S., Hahn I.H., Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology 1991, 30:558-562.
94. Singer H.S., Wendlandt J., Krieger M., Giuliano J. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599-604.
95. Smith-Hicks C.L., Bridges D.D., Paynter N.P., Singer H.S. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Movement Disorders 2007, 22:1764-1770.
96. Song J.H., Huang C.S., Nagata K., Yeh J.Z., Narahashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. Journal of Pharmacology and Experimental Therapy 1997, 282:707-714.
97. Spencer T.J., Sallee F.R., Gilbert D.L., Dunn D.W., McCracken J.T., Coffey B.J., et al. Atomoxetine treatment of ADHD in children with comorbid tourette syndrome. Journal of Attention Disorders 2008, 11:470-481.
98. Steeves T.D., Ko J.H., Kideckel D.M., Rusjan P., Houle S., Sandor P., et al. Extrastriatal dopaminergic dysfunction in Tourette syndrome. Annals of Neurology 2010, 67:170-181.
99. Steingard R.J., Goldberg M., Lee D., DeMaso D.R. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 1994, 33(3):394-399.
100. Strassnig M., Riedel M., Müller N. Electroconvulsive therapy in a patient with Tourette's syndrome and co-morbid obsessive compulsive disorder. The World Journal of Biological Psychiatry 2004, 5:164-166.
101. Swain J.E., Scahill L., Lombroso P.J., King R.A., Leckman J.F. Tourette syndrome and tic disorders: A decade of progress. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:947-968.
102. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetina on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006, 50:755-760.
103. Trivedi H.K., Mendelowitz A.J., Fink M. Gilles de la Tourette form of catatonia: Response to ECT. The Journal of ECT 2003, 19:115-117.
104. Ulloa C.M., Towfigh A., Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatric Disease and Treatment 2009, 5:467-476.
105. van Wattum P.J., Chappell P.B., Zelterman D., Scahill L.D., Leckman J.F. Patterns of response to acute naloxone infusion in Tourette's syndrome. Movement Disorders 2000, 15:1252-1254.
106. Wang S.M., Han C., Lee S.J., Patkar A.A., Pae C.U., Fleischhacker W.W. Paliperidone: A review of clinical trial data and clinical implications. Clinical Drug Investigation 2012, 32:497-512.
107. Wang L.J., Ree S.C., Huang Y.S., Hsiao C.C., Chen C.K. Adjunctive effects of aripiprazole on metabolic profiles: Comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013, 40:260-266.
108. Wokke J. Riluzole. Lancet 1996, 348:795-799.
109. Wong D.F., Singer H.S., Brandt J., Shaya E., Chen C., Brown J., et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. Journal of Nuclear Medicine 1997, 38:1243-1247.
110. Wu S.W., Shahana N., Huddleston D.A., Lewis A.N., Gilbert D.L. Safety and tolerability of theta-burst transcranial magnetic stimulation in children. Developmental Medicine and Child Neurology 2012, 54:636-639.
111. Yeh C.B., Lee C.H., Chou Y.H., Chang C.J., Ma K.H., Huang W.S. Evaluating dopamine transporter activity with 99mTc-TRODAT-1 SPECT in drug-naive Tourette's adults. Nuclear Medicine Communications 2006, 27:779-784.
112. Yeh C.B., Lee C.S., Ma K.H., Lee M.S., Chang C.J., Huang W.S. Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging. Psychiatry Research 2007, 156:75-82.
113. Yoon D.Y., Rippel C.A., Kobets A.J., Morris C.M., Lee J.E., Williams P.N., et al. Dopaminergic polymorphisms in Tourette syndrome: association with the DAT gene (SLC6A3). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2007, 144B:605-610.
114. Ziemann U., Paulus W., Rothenberger A. Decreased motor inhibition in Tourette's disorder: Evidence from transcranial magnetic stimulation. The American Journal of Psychiatry 1997, 154:1277-1284.